.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Phase III ALTA-1L Trial of Brigatinib for ALK-Rearranged NSCLC

EP. 1: A Retrospective Look at ALK-Rearranged NSCLC Management

February 4th 2020

EP. 2: Immuno- and Chemotherapy Approach to R/R NSCLC

February 4th 2020

EP. 3: The ALTA-1L Phase III Trial

February 4th 2020

EP. 4: ALTA-1L Regimen: Patient Selection Versus Other ALK TKIs

February 4th 2020

EP. 5: Managing ALK-Positive NSCLC Disease Progression

February 4th 2020

EP. 6: ALTA-1L Trial: Do Results Affect ALK TKI Sequencing?

February 4th 2020

EP. 7: Brigatinib Regulatory Status in NSCLC

February 4th 2020